Mario Amatruda, PhD, joined the CUNY Advanced Science Research Center’s Neuroscience Initiative in February 2017. He obtained his MSc degree in Biotechnology at the University Vita-Salute San Raffaele (Milan, Italy) in 2012. During his MSc, he investigated the role of neural progenitor cells in regulating the integrity of the blood-brain barrier in physiological conditions and after ischaemic stroke. In 2013, Mario joined the Institute of Neurology of the University College London (UK) where he received his PhD in Neuroscience in January 2017. His doctoral research was focused on the role of hypoxia and energy deficit in neuroinflammatory diseases, such as multiple sclerosis (MS). During his PhD, Mario received additional training in drug screening at Keregen Therapeutics (Stevenage, UK), where he examined the effects of Nrf2 activators for the treatment of MS.
Mario is currently studying the mechanisms contributing to CNS damage in neuroinflammatory/demyelinating diseases, focusing on the causes of mitochondrial dysfunction and neurodegeneration in MS. In particular, he combines animal models, in-vivo imaging, and molecular techniques to investigate the role of lipid signalling and homeostasis on neuronal function and neurological deficits. Ultimately, Mario’s research aims to identify new therapeutic targets and examine new treatments to protect the CNS from degenerating and decrease the severity of the disease.